Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026
NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Liuting, Cheng Feifei, Huang Yung-Hsing, Wang Yutong, He Jin, Liu Jiaqi, Wang Zhiming, Lin Pei, Fan Yihui, Bao Li, Yi Qing, Yang Jing
Аннотация
AIMS: Proteasome inhibitors (PIs) play a central role in multiple myeloma (MM) therapy; however, a substantial proportion of patients fail to achieve durable responses, resulting in early disease progression and limited long-term clinical benefit. This paper aims to understand the molecular mechanisms that constrain PI efficacy and drive resistance and explore a novel strategy for improving therapeutic outcomes in MM.
METHODS: By integrative analysis of multiple publicly available transcriptomic datasets from large MM patient cohorts, we identified sodium-hydrogen exchanger 6 (NHE6), encoded by SLC9A6. This gene emerged as a candidate gene associated with resistance to PI-based therapy. Functional studies were performed using patient-derived primary MM cells, PI-resistant MM cell lines, and preclinical mouse models.
RESULTS: NHE6 is highly expressed in MM cells with further upregulation in PI-nonresponsive disease. Elevated NHE6 expression is associated with reduced progression-free and overall survival. We demonstrate that NHE6 promotes acidification in the endosomal lumen, thereby facilitating early-to-late endosomal maturation and enhancing autophagic flux in MM cells. This process in turn attenuates PI-induced tumor cell apoptotic death. Consistent with this mechanism, genetic ablation or pharmacologic inhibition of NHE6 disrupted endosomal maturation, impaired autophagy, and markedly increased sensitivity to bortezomib and carfilzomib in vitro and in vivo PI-resistant models.
CONCLUSIONS: These findings identify an NHE6-mediated endosomal-autophagy axis as a previously unrecognized mechanism of PI resistance in MM. Targeting NHE6 represents a promising upstream strategy to restore apoptotic responses to PI-based therapies and improve therapeutic outcomes in refractory MM.
METHODS: By integrative analysis of multiple publicly available transcriptomic datasets from large MM patient cohorts, we identified sodium-hydrogen exchanger 6 (NHE6), encoded by SLC9A6. This gene emerged as a candidate gene associated with resistance to PI-based therapy. Functional studies were performed using patient-derived primary MM cells, PI-resistant MM cell lines, and preclinical mouse models.
RESULTS: NHE6 is highly expressed in MM cells with further upregulation in PI-nonresponsive disease. Elevated NHE6 expression is associated with reduced progression-free and overall survival. We demonstrate that NHE6 promotes acidification in the endosomal lumen, thereby facilitating early-to-late endosomal maturation and enhancing autophagic flux in MM cells. This process in turn attenuates PI-induced tumor cell apoptotic death. Consistent with this mechanism, genetic ablation or pharmacologic inhibition of NHE6 disrupted endosomal maturation, impaired autophagy, and markedly increased sensitivity to bortezomib and carfilzomib in vitro and in vivo PI-resistant models.
CONCLUSIONS: These findings identify an NHE6-mediated endosomal-autophagy axis as a previously unrecognized mechanism of PI resistance in MM. Targeting NHE6 represents a promising upstream strategy to restore apoptotic responses to PI-based therapies and improve therapeutic outcomes in refractory MM.